Market Place
Sourcing Support
REDUCE-IT Subanalysis on VASCEPA®/VAZKEPA® at AHA 2024
11 Nov 2024 //
GLOBENEWSWIRE
Macleods`s Generics Lansoprazole Receives Approval in US
04 Nov 2024 //
FDA
Amarin Reports Q3 2024 Financial Results & Provides Business Update
30 Oct 2024 //
GLOBENEWSWIRE
Amarin Announces Two Upcoming Investor Events
01 Oct 2024 //
GLOBENEWSWIRE
Research On VASCEPA To Be Presented At EASD Meeting
09 Sep 2024 //
GLOBENEWSWIRE
Amarin Reports Q2 2024 Results And Provides Business Update
31 Jul 2024 //
GLOBENEWSWIRE
Amarin To Report Q2 Results On July 31
17 Jul 2024 //
GLOBENEWSWIRE
Amarin`s VAZKEPA Gets National Reimbursement In Portugal
17 Jul 2024 //
GLOBENEWSWIRE
Amarin`s Partner Gets China Approval For VASCEPA In Cardiovascular Risk
08 Jul 2024 //
GLOBENEWSWIRE
After Stock crash and Staff cuts, Amarin wins bid to revive Vascepa patent
26 Jun 2024 //
FIERCE PHARMA
Amarin Board of Directors Announces CEO Transition
04 Jun 2024 //
GLOBENEWSWIRE
Amarin: VAZKEPA Reimbursed In Greece, Deal With Vianex For Commercialization
28 May 2024 //
GLOBENEWSWIRE
Amarin Reports First Quarter 2024 Business Update and Financial Results
01 May 2024 //
GLOBENEWSWIRE
Amarin Applauds Petition Urging FDA Fenofibrate Action
24 Apr 2024 //
GLOBENEWSWIRE
Amarin Announces Results of Annual General Meeting of Shareholders
22 Apr 2024 //
GLOBENEWSWIRE
Enforcement Report - Week of April 17, 2024
17 Apr 2024 //
FDA
Amarin Q1 2024 Results, Call On 5/1
15 Apr 2024 //
GLOBENEWSWIRE
Amarin Highlights Key Data at ACC.24
08 Apr 2024 //
GLOBENEWSWIRE
New REDUCE-IT® Analyses Show VASCEPA Benefit in High-Risk Cardiovascular Disease
06 Apr 2024 //
GLOBENEWSWIRE
Amarin Provides Update on VAZKEPA® Intellectual Property Portfolio in Europe
03 Apr 2024 //
GLOBENEWSWIRE
Teva, like Hikma, accuses Amarin of hoarding Vascepa ingredient
30 Mar 2024 //
FIERCE PHARMA
Amarin to Report Fourth Quarter and Full Year 2023 Financial Results
15 Feb 2024 //
GLOBENEWSWIRE
Enforcement Report - Week of February 14, 2024
14 Feb 2024 //
FDA
Amarin Chairman & CEO Issue Letter to Shareholders
22 Jan 2024 //
GLOBENEWSWIRE
Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials
10 Jan 2024 //
GLOBENEWSWIRE
Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference
11 Dec 2023 //
GLOBENEWSWIRE
Analyses Show VASCEPA Associated with 29% Reduction with Metabolic Syndrome
12 Nov 2023 //
GLOBENEWSWIRE
Amarin Reports Third Quarter 2023 Financial Results
01 Nov 2023 //
GLOBENEWSWIRE
Amarin Appoints Jonathan Provoost Executive Vice President
31 Oct 2023 //
GLOBENEWSWIRE
Latest Research Evaluating VASCEPA/VAZKEPA Trial to be Presented
26 Oct 2023 //
GLOBENEWSWIRE
Amarin to Report Third Quarter 2023 Financial Results
19 Oct 2023 //
GLOBENEWSWIRE
Amarin to Present at the 2023 Cantor Global Healthcare Conference
12 Sep 2023 //
GLOBENEWSWIRE
Amarin Provides Pricing & Reimbursement Updates for VAZKEPA
09 Aug 2023 //
GLOBENEWSWIRE
Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA
08 Aug 2023 //
GLOBENEWSWIRE
Scottish Medicines Consortium Accepts VAZKEPAto Help Reduce Cardiovascular Risk
07 Aug 2023 //
GLOBENEWSWIRE
Amarin Reports Second Quarter 2023 Financial Results
02 Aug 2023 //
GLOBENEWSWIRE
Amarin and Lotus Pharma Announce Partnership Agreement to Commercialize Vazkepa
31 Jul 2023 //
GLOBENEWSWIRE
Research Evaluating Clinical Benefits of VASCEPA/VAZKEPA to be Presented at ESC
26 Jul 2023 //
GLOBENEWSWIRE
Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA
25 Jul 2023 //
GLOBENEWSWIRE
Amarin Board of Directors Announces Compensation Program for President and CEO
20 Jul 2023 //
GLOBENEWSWIRE
Amarin axes 120 of its 385 employees, hires new CEO Patrick Holt
20 Jul 2023 //
FIERCE PHARMA
Amarin axes 120 of its 385 employees, hires new CEO Patrick Holt
19 Jul 2023 //
FIERCE PHARMA
Amarin Implements Organizational Restructuring to Strengthen the Company
18 Jul 2023 //
GLOBENEWSWIRE
Amarin Appoints Patrick Holt as President and Chief Executive Officer
18 Jul 2023 //
GLOBENEWSWIRE
SFDA approves Amarin’s VASCEPA to reduce CV risk in Saudi Arabia
22 Jun 2023 //
PHARMACEUTICAL TECHNOLOGY
Amarin to Present at Two Upcoming Investor Conferences
01 Jun 2023 //
GLOBENEWSWIRE
Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa
01 Jun 2023 //
GLOBENEWSWIRE
Amarin Highlights Data Providing Insight into Vascepa/Vazkepa (Icosapent Ethyl)
12 May 2023 //
GLOBENEWSWIRE
Amylyx welcomes former Alnylam exec; Amarin plugs in an interim chief
21 Apr 2023 //
ENDPTS
Amarin to Report 1Q 2023 FYR and Host Conference Call on May 3, 2023
19 Apr 2023 //
GLOBENEWSWIRE
Amarin Names Aaron Berg Interim President & Chief Executive Officer
17 Apr 2023 //
GLOBENEWSWIRE
Amarin names new interim CEO and board member
17 Apr 2023 //
FIERCE PHARMA
Amarin Announces VAZKEPA Approved by Israel`s Ministry of Health
05 Apr 2023 //
PRESS RELEASE
Amarin Announces VAZKEPA Approved by Israel`s Ministry of Health
04 Apr 2023 //
GLOBENEWSWIRE
After Amarin`s clash with Sarissa, CEO Mikhail hits the exit
01 Apr 2023 //
FIERCE PHARMA
Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA
16 Mar 2023 //
GLOBENEWSWIRE
With 7 board resignations, Sarissa strengthens control of Amarin
07 Mar 2023 //
FIERCE PHARMA
Amarin Highlights Evidence of Value of EPA in Reducing Cardiovascular Events
06 Mar 2023 //
GLOBENEWSWIRE
Amarin Announces Board Departures
06 Mar 2023 //
GLOBENEWSWIRE
Amarin Announces REDUCE-IT Data at ACC.23 Showing Benefit of VASCEPA/VAZKEPA
05 Mar 2023 //
GLOBENEWSWIRE
